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Abstract
Acute generalized exanthematous pustulosis (AGEP) is a rare cutaneous adverse reaction characterized by acute
sterile pustular eruptions, mostly induced by medications. Antibiotics are the most commonly implicated drugs;
however, there have only been two previous reports of vancomycin-induced AGEP in the literature. In this case, we
present the clinical course of a 56-year-old man who was admitted to the intensive care unit with an unusually
severe form of AGEP mimicking septic shock, which developed after the recent use of vancomycin. Despite
cessation of the offending agent, our patient continued to clinically decline with development of worsening skin
eruptions and hemodynamic instability necessitating vasopressor support. The patient promptly responded to
systemic steroid therapy with complete resolution of AGEP. In addition to highlighting the implication of vancomycin
in AGEP, we herein discuss the clinical presentation, diagnosis, and management of AGEP, particularly in severe cases
admitted to the intensive care unit.
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Background
Acute generalized exanthematous pustulosis (AGEP) is a
rare disorder characterized by an acute-onset severe cuta-
neous reaction manifesting as several non-follicular pus-
tules on a diffuse erythematous edema [1, 2]. It is usually a
drug-related reaction, with antibiotics most commonly im-
plicated [2]. It is typically a self-limited condition that re-
solves spontaneously with cessation of the offending
agent. While it typically has systemic features such as fever
and leukocytosis, it rarely causes multi-organ involvement
[3]. Herein, we describe a unique case of vancomycin-
induced AGEP in a middle-aged male presenting with
distributive shock and multi-org.
Case presentation
A 56-year-old man with newly diagnosed glioblastoma
multiforme underwent craniotomy and tumor resection
followed by external beam radiation and concurrent
chemotherapy with temozolomide. His post-operative
course was complicated by an epidural abscess, which
was initially drained. Fluid cultures revealed methicillin-
resistant streptococcus epidermitis (MRSE). The patient
subsequently underwent resection of the abscess followed
by cranioplasty with placement of a vancomycin-
impregnated titanium mesh to repair the skull defect. He
was discharged home on a course of steroid therapy for
vasogenic edema noted on post-operative brain MRI as
well as an 8-week course of intravenous vancomycin ad-
ministered via a peripherally inserted central catheter. His
steroid taper was dexamethasone 4 mg po twice a day for
3 days, then 2 mg twice a day for 3 days, then 2 mg once a
day for 3 days, and 1 mg once a day for 3 days.
The patient tolerated the antibiotic infusion well. Two
weeks later, having completed his dexamethasone taper
2 days prior, he presented to the emergency department
complaining of a diffuse red, itchy rash. He also reported
experiencing fevers reaching 38 °C and chills over the
past day. He denied any face or tongue swelling, nausea,
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vomiting, abdominal pain, or diarrhea. He reported no
prior skin rashes or allergic reactions and no new medi-
cations or other antibiotics. He was not on any other
medications except the IV antibiotic infusion.
On presentation, the patient was febrile at 38.4 °C,
tachycardic at 130/min, tachypneic at 32/min, hypotensive
at 88/55 mmHg, and saturating 96 % on room air. Physical
examination revealed numerous small studded pustules on
an erythematous background on the forehead, frontal
scalp, cheeks, trunk, upper and lower extremities, and ax-
illa, with numerous erythematous macules and papules
coalescing into plaques noted on the back, trunk, and ex-
tremities (Fig. 1). There was no evidence of mucous mem-
brane involvement, lymphadenopathy, or organomegaly.
There was no neck stiffness, changes in speech, numbness,
or weakness. Initial laboratory studies revealed a normal
white blood cell count (9200/μL) with a left shift (22 %
bands) and without eosinophilia, an elevated lactate level
(3.2 mmol/L), normal TSH, and minimally elevated C-
reactive protein and erythrocyte sedimentation rate. His
serum creatinine was 1.2 mg/dL with GFR of 89 mL/min.
His liver function tests were mildly elevated (AST 56 IU/L;
ALT 50 IU/L).
The patient was aggressively resuscitated with multiple
intravenous crystalloid fluid boluses. Vancomycin was
stopped and intravenous linezolid was started. Chest
radiograph was normal. Brain MRI did not show evi-
dence of leptomeningeal enhancement or signs of recur-
rent infection. Abdominal ultrasound was unremarkable.
The patient was admitted to the infectious disease ward
to undergo further work-up. Dermatology was consulted
and skin biopsies were obtained. He was started on top-
ical steroids for the skin rash, which was suspected to be
acute generalized exanthematous pustulosis. However,
the patient continued to have fevers, and he remained
tachycardic, tachypneic, and hypotensive despite mul-
tiple intravenous fluid boluses. His urine output became
diminished and his mental status became depressed. His
antibiotic coverage was broadened to include intra-
venous cefepime and metronidazole in addition to li-
nezolid. He was transferred overnight to the medical
intensive care unit for escalation of care and sus-
pected septic shock.
While in the intensive care unit, the patient was con-
tinued on empiric broad-spectrum antibiotic coverage
and given additional intravenous fluid boluses. He con-
tinued to have tachycardia, tachypnea, increased work of
breathing, and fevers reaching 39 °C. The skin examin-
ation worsened, with more diffuse skin involvement and
development of edema of the face. Laboratory investiga-
tion revealed bandemia (28 %). He developed increasing
somnolence, reduced urine output, signs of volume over-
load with elevated central venous pressure (14 mmHg),
and increasing oxygen requirements. Vasopressors were
started for hypotension. The infectious work-up was nega-
tive to date, including multiple sets of negative blood cul-
tures. Histopathological examination of the skin punch
biopsy revealed sub-corneal and intraepidermal pustules,
widespread spongiosis, and neutrophil infiltration around
the vessels in the papillary dermis—findings consistent
with acute generalized exanthematous pustulosis (Fig. 2).
In light of the patient’s worsening clinical status and ap-
parent lack of response to topical steroids, he was started
on high-dose steroids with Solu-Medrol 80 mg IV daily
per recommendations from the dermatology consult team.
The patient’s weight was 79.5 kg; thus, steroid dosing was
determined using 1 mg/kg dosing calculation, which has
Fig. 1 Day 3 of hospital admission, before initiation of systemic
steroid therapy. Numerous small studded pustules on an erythematous
background with numerous erythematous macules and papules
coalescing into plaques are noted in various body parts
Fig. 2 Histopathology of skin biopsy revealing spongiotic epidermis
with focal parakeratosis, exocytosis, and spongiotic vesicles, along
with papillary dermal edema, superficial dermal perivascular
inflammatory infiltrate, and mixed dermal interstitial inflammation
with eosinophils (H&E, ×10). The arrow points to the "papillary dermal
edema and superficial dermal perivascular inflammatory infiltrate"
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been shown to be an effective starting dose for severe
AGEP and similar dermatologic conditions.
The patient responded remarkably well to the systemic
steroids. He had rapid clinical improvement and within
hours became afebrile, was weaned off of the vasopres-
sors, and had complete resolution of his tachycardia and
tachypnea. His mental status improved, urine output in-
creased, and respiratory status normalized. Within 24 h,
the skin rash had regressed significantly (Fig. 3). The
antibiotics were discontinued, except for linezolid. Intra-
venous Solu-Medrol was transitioned to prednisone
80 mg oral daily. The patient was discharged home in
stable condition on a prednisone taper, planned to be ti-
trated down by 10 mg weekly. He was also discharged
on linezolid 600 mg oral twice a day to complete his ini-
tial antibiotic course. Six months later, the patient has
completed his antibiotic and steroid treatment courses
and continues to do well. The patch test for vancomycin
was deemed unnecessary by the dermatology consult
team because the patient was not on any home medica-
tions aside from steroids and vancomycin; thus, the only
obvious culprit was vancomycin. In vitro testing such as
macrophage migration inhibition factor (MIF) test or
mast cell degranulation (MCD) test were not performed,
as these are unavailable at our institution.
Discussion
AGEP is a rare disorder characterized by the acute de-
velopment of sterile, non-follicular pinhead-sized pustu-
lar eruptions overlying an edematous erythema [1, 2].
Characteristically, the skin reaction arises rapidly within
a few hours and tends to resolve quickly within several
days after cessation of the offending agent or may re-
solve spontaneously. The rash mostly begins in the
intertriginous areas or in the face then spreads dif-
fusely and is often described as a burning or itching
sensation. In about 20 % of cases, mucous mem-
branes are involved but tend to be mild and usually
limited to the oral cavity [1].
The incidence of AGEP has been approximated at 1 to
5 cases per million annually [4]. More than 90 % AGEP
cases are related to drugs, with viruses comprising the
next most common trigger. The most commonly im-
plicated drugs are antibiotics, including pristinamycin,
ampicillin, amoxicillin, macrolides, and quinolones.
Other drugs include calcium channel blockers and an-
tifungal agents [2]. Although sulfa drugs can cause
many skin reactions, they are usually not implicated
in AGEP [5].
AGEP commonly presents with high fevers and neu-
trophilia concurrently occurring with the skin eruptions,
thus often misinterpreted as an acute infectious disease.
It tends to occur suddenly within 1 to 2 days of exposure
to the offending agent and is generally self-limited when
the causative agent is eliminated. The skin pustules typ-
ically begin on the face and within hours spread to the
trunk and limbs and tend to coalesce. Multi-organ in-
volvement is rare and highly atypical of AGEP [3, 6].
Histological evaluation of the involved skin shows
spongiform subcorneal and intraepidermal pustules,
papillary dermal edema, and neutrophilic infiltration
around papillary dermal blood vessels [1].
Important differential diagnoses for AGEP include
Stevens-Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN). The systemic features of AGEP usually
manifest early, whereas SJS/TEN tends to have a slower
manifestation, usually after 3 weeks, and characteristic-
ally presents with blisters and severe mucus membrane
involvement. Furthermore, the drugs implicated in SJS/
TEN are usually different, such as antiepileptic agents or
allopurinol [7].
A useful algorithm for the diagnosis of AGEP was
proposed by Sidoroff et al. [1]. The validation score
combines clinical and histological features, such as the
type and distribution of the skin rash, presence of
leukocytosis, histological findings, and the timing of the
skin reaction. A score of 8 to 12 is definitive for the
diagnosis of AGEP. Applying the AGEP validation score
resulted in a score of 11 in our patient, confirming the
diagnosis.
Typically self-limiting in nature, AGEP tends to re-
solve spontaneously with cessation of the offending
agent and no further measures are usually required. The
use of steroids is not routinely required and if indicated,
usually topical steroids suffice in providing clinical im-
provement [6]. Systemic steroids have been used on rare
occasions when AGEP presents atypically with severe
systemic involvement [8–10].
Our case has several unique features. First, the onset
of AGEP was delayed for a couple of weeks after
Fig. 3 Day 4 of hospital admission, after initiation of systemic steroid
therapy. Significant regression of skin eruptions noted
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initiation of the offending antibiotic, and this was most
likely because the patient was on concurrent steroid
therapy for his vasogenic cerebral edema. Immediately
following completion of the steroid therapy, and hence
loss of its anti-inflammatory effects, AGEP was abruptly
unmasked.
Second, in contrast to most reported cases of AGEP,
our case demonstrates an atypical presentation with se-
vere systemic involvement and multi-organ failure mim-
icking septic shock. The clinical presentation continued
to deteriorate despite cessation of the offending anti-
biotic. Because the patient was only on a brief (12 days)
and tapered-down course of steroid therapy, it was not
felt that his hemodynamic instability was secondary to
adrenal insufficiency, and thus, this was not worked up
with laboratory testing.
Third, the presence of antibiotic-impregnated intracra-
nial mesh added another layer of complexity to our case,
as it was not evident what role this played in our patient’s
clinical picture. While there is scarce data in current
literature on this particular matter, it has been reported
that systemic absorption and side effects in antibiotic-
impregnated orthopedic implants are usually minimal
[11]. However, given the continued clinical decline of our
patient after cessation of the systemic antibiotic, one may
speculate about the potential contribution of antibiotic re-
lease from the intracranial mesh.
Fourth, the role of systemic steroids in the manage-
ment of AGEP is rarely indicated and topical steroids
usually suffice if the disorder does not resolve with ces-
sation of the offending agent [3]. However, as our case
illustrates, despite the use of topical steroids, the pa-
tient’s skin eruptions progressed rapidly coinciding with
rapid clinical decline, hemodynamic instability, and
multi-organ involvement necessitating vasopressors. Ad-
ministration of high-dose intravenous steroids resulted
in rapid clinical improvement.
Finally, vancomycin as a cause of AGEP is exception-
ally rare. To the best of our knowledge, there have only
been three previously reported cases of vancomycin-
induced AGEP in the literature [8, 9, 12]. One case in-
cluded another confounding antibiotic that is more com-
monly implicated in AGEP, and thus, the causation
relationship was equivocal. The second case presented
typically with resolution of AGEP following cessation of
vancomycin, with no additional required interventions
such as steroids. And the third case presented atypically
with a severe AGEP course similar to our case and re-
quired systemic steroids. In the latter case, the patient
required only several days of systemic steroids with
complete clinical recovery. However, because of the pres-
ence of vancomycin-impregnated intracranial mesh in our
patient with unclear clinical significance, a prolonged sys-
temic steroid taper was chosen for our patient.
Conclusion
AGEP is a rare disorder characterized by acute onset of
characteristic skin eruptions, often triggered by certain
medications. This condition is typically self-limiting in
nature and tends to resolve spontaneously with cessation
of the offending agent. The use of steroids is not rou-
tinely required. However, as this case illustrates, AGEP
could present atypically with aggressive multi-organ in-
volvement and hemodynamic compromise mimicking
septic shock despite cessation of the offending agent. In
such cases, early systemic steroid administration appears
to provide immediate hemodynamic stabilization and
clinical improvement.
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